Video

Dr. Kumar Discusses Advances in the Field of Multiple Myeloma

Author(s):

Shaji K. Kumar, MD

In Partnership With:

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses advances in the field of multiple myeloma.

Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses advances in the field of multiple myeloma.

The field of multiple myeloma, especially in the newly diagnosed patients, is moving forward, says Kumar.

The first completely oral treatment for newly diagnosed patients with multiple myeloma is ixazomib (Ninlaro), lenalidomide (Revlimid) and dexamethasone, which is under investigation now.

Related Videos
Breelyn Wilky, director, Sarcoma Medical Oncology, The Cheryl Bennett and McNeilly Family Endowed Chair in Sarcoma Research, deputy associate director, Clinical Research, associate professor, medicine, medical oncology, the University of Colorado Medicine
Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Kimberly Cannavale, MPH
Rahul Banerjee, MD, FACP
Grzegorz S. Nowakowski, MD
Katharine A. Price, MD
Robert Z. Orlowski, MD, PhD, and Jonathan Kaufman, MD
Robert Z. Orlowski, MD, PhD, and Jonathan Kaufman, MD
Richard Kim, MD
Alexey Danilov, MD, PhD
Related Content
Sagar Lonial, MD, FACP
September 13th 2024

Myeloma Molecular Profiling Reveals Unique Copy Number and Expression Subtypes

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Susan L. Slager, PhD
September 10th 2024

Mayo Clinic Study Finds Dysfunctional White Blood Cells Linked to Heightened Melanoma Risk

Seth Wander, MD, PhD; Paolo Tarantino, MD; Daniel P. Petrylak, MD; Lionel A. Kankeu Fonkoua, MD; Solange Peters, MD, PhD; Edgardo Santos, MD, FACP, FCCP
October 9th 2023

Expert Insights on the United States Chemotherapy Shortage

Meletios A. Dimopoulos, MD, professor, chairman, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine
September 6th 2024

D-VRd Improves MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Myeloma

The FDA has approved a new presentation of bortezomib for subcutaneous or intravenous administration.
September 6th 2024

FDA Approves Bortezomib Injectable for Multiple Myeloma and MCL